-

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences:

  • Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST
  • Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 1:30 p.m. GMT

The live audio webcast of each presentation will be accessible on the Investors section of the Company’s website at www.ir.kalvista.com/event-calendar. An archived replay will be available approximately two hours after the completion of the events.

About KalVista Pharmaceuticals, Inc.
KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.

Contacts

Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com

Media:
Molly Cameron
Director, Corporate Communications
(857) 356-0164
molly.cameron@kalvista.com

Industry:

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV
Release Versions
English

Contacts

Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com

Media:
Molly Cameron
Director, Corporate Communications
(857) 356-0164
molly.cameron@kalvista.com

More News From KalVista Pharmaceuticals, Inc.

KalVista, a Company of the Chiesi Group, Reinforces Its Commitment to the Hereditary Angioedema (HAE) Community with New Real-World and Clinical Research Presented at the ACAAI Annual Meeting

FRAMINGHAM, Mass.--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”), a company of the Chiesi Group, today announced the presentation of new clinical and real-world research evaluating sebetralstat at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix (November 12-16). The five presentations highlight patient-reported satisfaction with sebetralstat, reasons for treatment switching, long-term health-related quality-of-life (QoL)...

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of therapies for rare and ultra-rare conditions. With the completion of the transac...

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben Palleiko, Chief Executive Officer of KalVista. “Currentl...
Back to Newsroom